John F. Forbes
University of Limerick
373 Papers
2.2K Citations
John F. Forbes is an academic researcher from University of Limerick. The author has contributed to research in topics: Breast cancer & Tamoxifen. The author has an hindex of 88, co-authored 368 publications. Previous affiliations of John F. Forbes include University of Newcastle & University of Melbourne.
Chat about Author
Papers
Mortality results for randomised controlled trial of early elective surgery or ultrasonographic surveillance for small abdominal aortic aneurysms. The UK Small Aneurysm Trial Participants
Roger M. Greenhalgh,A. R. Brady,Louise Brown,John F. Forbes,F. G. R. Fowkes +4 more
- 01 Jan 1998
TL;DR: In this article, the authors investigated whether prophylactic open surgery decreased long-term mortality risks for small aneurysms and found that the risk of rupture seems to be low for small abdominal aortic anusms smaller than 5 cm.
1K
Overview of the main outcomes in breast-cancer prevention trials.
Jack Cuzick,Thomas Powles,Umberto Veronesi,John F. Forbes,Robert Edwards,Stanley W. Ashley,Peter Boyle +6 more
TL;DR: Although tamoxifen cannot yet be recommended as a preventive agent (except possibly in women at very high risk with a low risk of side-effects), continued follow-up of the current trials is essential for identification of a subgroup of high-risk, healthy women for whom the risk-benefit ratio is sufficiently positive.
984
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials
Bernard Asselain,William E. Barlow,John M. S. Bartlett,Jonas Bergh,Elizabeth Bergsten-Nordström,Judith M Bliss,Francesco Boccardo,Clare Boddington,Jan Bogaerts,Gianni Bonadonna,Rosie Bradley,Etienne Brain,Jeremy P Braybrooke,Philippe Broët,John Bryant,Julie Ann Burrett,David Cameron,Mike Clarke,Alan S. Coates,Robert E. Coleman,Raoul Charles Coombes,C Correa,J. Costantino,Jack Cuzick,David N. Danforth,Nancy E. Davidson,C Davies,Lucy Davies,Angelo Di Leo,David Dodwell,Mitch Dowsett,Fran Duane,Vaughan Evans,Marianne Ewertz,Bernard Fisher,John F. Forbes,Leslie G. Ford,Jean-Claude Gazet,Richard D. Gelber,Lucy Gettins,Luca Gianni,Michael Gnant,Jon Godwin,Aron Goldhirsch,Pamela J. Goodwin,Richard Gray,Daniel F. Hayes,Catherine Hill,James N. Ingle,Reshma Jagsi,Raimund Jakesz,Sam James,Wolfgang Janni,Hui Liu,Z Liu,Caroline Lohrisch,Sibylle Loibl,Liz MacKinnon,Andreas Makris,Eleftherios P. Mamounas,Gurdeep S. Mannu,Miguel Martín,Simone Mathoulin,Louis Mauriac,Paul McGale,Theresa McHugh,Philip Morris,Hirofumi Mukai,Larry Norton,Yasuo Ohashi,Ivo A. Olivotto,Soon Paik,Hongchao Pan,Richard Peto,Martine Piccart,Lori J. Pierce,Philip Poortmans,Trevor J. Powles,Kathy Pritchard,Joseph Ragaz,Vinod Raina,Peter M. Ravdin,Simon Read,Meredith M. Regan,John F.R. Robertson,Emiel J. Th. Rutgers,Suzy Scholl,Dennis J. Slamon,Lidija Sölkner,Joseph A. Sparano,Seth M. Steinberg,Rosemary Sutcliffe,Sandra M. Swain,Carolyn W. Taylor,Andrew Tutt,Pinuccia Valagussa,Cornelis J.H. van de Velde,Jos van der Hage,Giuseppe Viale,Gunter von Minckwitz,Yaochen Wang,Zhe Wang,Xiang Wang,Timothy J. Whelan,Nicholas Wilcken,Eric P. Winer,Norman Wolmark,William C. Wood,Milvia Zambetti,Jo Anne Zujewski +109 more
TL;DR: Tumours downsized by NACT might have higher local recurrence after breast-conserving therapy than might tumours of the same dimensions in women who have not received NACT.
Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98
Alan S. Coates,Aparna Keshaviah,Beat Thürlimann,Henning T. Mouridsen,Louis Mauriac,John F. Forbes,Robert Paridaens,Monica Castiglione-Gertsch,Richard D. Gelber,Marco Colleoni,István Láng,Lucia Del Mastro,Ian E. Smith,Jacquie Chirgwin,J.M. Nogaret,Tadeusz Pienkowski,Andrew M Wardley,Erik Jakobsen,Karen N. Price,Aron Goldhirsch +19 more
TL;DR: The present updated analysis, which was limited to patients on monotherapy arms in BIG 1-98, yields results similar to those from the previous primary analysis but more directly comparable with results from other trials of continuous therapy using a single endocrine agent.
948
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses
Michael Baum,Aman U. Buzdar,Jack Cuzick,John F. Forbes,Joan Houghton,Anthony Howell,T Sahmoud +6 more
TL;DR: The results of the first efficacy update are reported along with the results of an updated safety analysis, performed 7 months after the first analysis, based on a median follow‐up period of 47 months.
867